<DOC>
	<DOC>NCT02746445</DOC>
	<brief_summary>The purpose of this study is to continue to evaluate the long-term effectiveness of Magnetic EEG/ECG-Guided Resonance Therapy (MeRT) in children with Autism Spectrum Disorder (ASD). No active MeRT treatment will be performed in this study.</brief_summary>
	<brief_title>A Longitudinal Study on the Safety and Efficacy for Subjects With ASD Who Received MeRT</brief_title>
	<detailed_description>This clinical trial is a longitudinal study designed to evaluate the safety and efficacy for subjects with Autism Spectrum Disorder (ASD) who received Magnetic EEG/ECG-Guided Resonance Therapy (MeRT) in the IRB approved clinical trial. A total of twenty-eight (28) subjects will be followed in this study. After providing informed consent, twenty-eight (28) subjects who participated in the previous protocol will be observed for up to three (3) years post-MeRT treatment. During this period, subjects will be evaluated at 104 and 156 weeks post-MeRT treatment.</detailed_description>
	<mesh_term>Autism Spectrum Disorder</mesh_term>
	<mesh_term>Autistic Disorder</mesh_term>
	<criteria>1. Subject must have completed the MeRT001 (formerly known as MRT001) clinical trial conducted by the Brain Treatment Center (BTC) 2. Age between 6 and 15 years (at day of informed consent) 3. Willing and able to adhere to the study visits 1. Subjects who did not participate in the MeRT001 clinical trial. 2. Any condition which in the judgment of the investigator would prevent the subject from completion of the study.</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Autism</keyword>
	<keyword>ASD</keyword>
	<keyword>Autism Spectrum Disorder</keyword>
</DOC>